Alligator Bioscience’s Q3 is out – comments from the CEO

Swedish Alligator Bioscience recently published its report for the third quarter – a period with significant progress in its pipeline projects.

BioStock talked to CEO Søren Bregenholt to learn more about reached milestones, the latest developments and his expectations for the near term. Immuno-oncology company Alligator Bioscience develops tumour-directed antibody-based treatments against cancer, based on.